Mansoor Arain, MD
Interventional Cardiology · Santa Maria, CANPI 1649531625
Payments from drug & device makers
Across 123 payments — averaging $193.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$14K
- Medtronic$6K
- Edwards Lifesciences$1K
- Philips North America LLC$1K
- Boston Scientific$874
- Abbott$745
- plus $266 from 9 others
What the payments were for
- Speaking & faculty fees$12,90054%
- Grants$5,00021%
- Travel & lodging$7333%
- Food & beverage$4,38118%
- Education$7373%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 27 | $14,008 |
| Medtronic(2 entities) | 24 | $5,666 |
| Edwards Lifesciences | 26 | $1,162 |
| Philips North America LLC | 6 | $1,029 |
| Boston Scientific | 14 | $874 |
| Abbott | 13 | $745 |
| Novartis | 3 | $61 |
| Biosense Webster, Inc. | 1 | $43 |
| Johnson & Johnson | 2 | $42 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $36 |
| Boehringer Ingelheim | 1 | $21 |
| BD | 1 | $20 |
| Cardiva Medical, Inc. | 1 | $17 |
| AstraZeneca | 1 | $16 |
| W. L. Gore & Associates, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$13,381
- (BQ9) Coronary IVUS$651
- SAPIEN 3 Ultra RESILIA$308
- GENERAL - THERAPIES$192
- Resolute$140
- SYNERGY$125
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$123
- MitraClip System$120
- MitraClip$119
- TRICLIP$116
- (6571) Eagle Eye$115
- GENERAL CATHETER$114
- XIENCE SKYPOINT$113
- (P84) IGT Devices Systems$113
How this compares
$23,751 in reported general payments places this provider in the 65th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 130 | $134,242 |
| JardianceEmpagliflozin | 54 | $69,197 |
| EntrestoSacubitril/Valsartan | 43 | $63,139 |
| Repatha SyringeEvolocumab | 29 | $24,235 |
| BrilintaTicagrelor | 16 | $12,170 |
| VascepaIcosapent Ethyl | 14 | $6,220 |
| Rosuvastatin Calcium | 327 | $6,108 |
| Ezetimibe | 93 | $4,779 |
| Metoprolol Succinate | 226 | $3,401 |
| Icosapent Ethyl | 12 | $2,791 |
| ClopidogrelClopidogrel Bisulfate | 209 | $2,310 |
| Atorvastatin Calcium | 172 | $1,920 |
| Pantoprazole Sodium | 57 | $730 |
| Amlodipine Besylate | 93 | $718 |
| FenofibrateFenofibrate Nanocrystallized | 23 | $691 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $21 | $69,19754 claims |
| NovartisEntresto | $61 | $63,13943 claims |
| AstraZenecaBrilinta | $16 | $12,17016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Santa Maria
- Samir BhattSanta Maria$323K
- Rajendra MakkarWest Hollywood$16.6M
- Fahed BitarCovina$9.9M
- Rahul SharmaStanford$6.6M
- Matthew Pricela Jolla$5.8M
- David LeeStanford$5.7M
- Saibal KarThousand Oaks$5.4M
- Mehrdad ArianiNorthridge$5M
- Frederick St GoarMountain View$4.2M
- Sammy ElmariahSan Francisco$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.